SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending following an analyst upgrade and renewed interest in quantum computing stocks, with community members debating whether the sector is overheating or poised for further gains.  Bulls cite long-term potential and momentum, while bears point to valuation concerns and the possibility of a near-term correction or share offering.  The stock's volatile price action is fueling discussions around short squeezes and market manipulation.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is trending as the community discusses its recent upward momentum and potential for further gains, with some eyeing a squeeze. Bullish investors are eagerly anticipating news and regulatory milestones, while also debating potential government involvement in the sector. Talk centers around technical analysis, short positions, and the long-term prospects of deep-sea mining for critical minerals.

Galecto, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The firm is also involved in the development of small molecule inhibitors of galectin-3 and LOXL2. The company was founded by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye in 2011 and is headquartered in Boston, MA.

Galecto Inc

GLTO is trending due to significant pre-market price action and high trading volume, reminiscent of recent runs by other stocks like SPRB. The community is actively discussing potential reasons for the surge, including a possible short squeeze and comparing it to other high-flying tickers. Some traders are noting the lack of specific news catalysts while others speculate about possible undisclosed developments related to its oncology and liver disease treatments.

Siyata Mobile, Inc. engages in the provision of cellular communications systems for enterprise customers. It specializes in connected vehicle products for professional fleets, marketed under the Uniden Cellular and Siyata brands. The firm operates through the following geographical segments: Europe, the Middle East and Africa; Unites States; Canada; and Australia and New Zealand. The company was founded by Marc Seelenfreund on October 15, 1986 and is headquartered in Montreal, Canada.

Core AI Holdings Inc.

Core AI Holdings, Inc.

Core AI Holdings ($CHAI) is trending as the merger with Core Gaming finalizes, with the new ticker set to debut soon, though some users report trading difficulties on certain platforms. The community is weighing the impact of the merger and reverse split, while also speculating on future performance and potential short squeezes. Some are optimistic about the AI gaming sector and the company's revenue, while others voice concerns over platform issues and potential dilution.

NuCana Plc is a clinical stage biopharmaceutical company. It engages in the business of developing a portfolio of new medicines to treat patients with cancer. The company was founded by Hugh Stephen Griffith and Christopher Barry Wood on January 28, 1997 and is headquartered in Edinburgh, the United Kingdom.

NuCana plc - ADR

NuCana plc

NuCana ($NCNA) is trending as traders discuss its low float and potential for a squeeze, drawing comparisons to $SPRB's recent surge. Anticipation is building around upcoming cancer treatment data presentations in October, with some speculating on merger possibilities and significant price targets. The community notes the company's strong cash runway into 2029, which further fuels optimism.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum Inc. ($QBTS) is trending amid discussions about a potential short squeeze and overall momentum in the quantum computing sector. Community members are debating the company's valuation and future prospects, with some highlighting its potential in AI and clean technology, while others express concerns about dilution and competition from larger tech companies. There's also speculation about potential partnerships or acquisitions, contributing to the stock's recent volatility.

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPY is seeing increased volatility, with community chatter focused on whether a significant downturn is imminent. Mixed sentiment abounds, with some traders taking profits and anticipating a larger correction, while others are buying the dip expecting a quick recovery. News impacting AI-related stocks and broader economic concerns like inflation and government shutdowns also appear to be influencing market sentiment.

Quantum Computing, Inc. engages in developing novel algorithms and solutions utilizing quantum and quantum-inspired computing to solve difficult problems in various industries. It leverages its expertise in finance, computing, security, mathematics, and physics to develop commercial applications for the financial, security, and government sectors. The company was founded on July 25, 2001 and is headquartered in Hoboken, NJ.

Quantum Computing Inc

QUBT is trending as investors discuss the implications of a recent private placement and its impact on the company's cash position and future strategy. Community members are debating the stock's valuation, potential acquisitions, and its position relative to other quantum computing companies. Some are bullish, citing the strong institutional demand, while others express concerns about dilution and question the long-term commercial viability of the technology.

Spruce Biosciences, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. The company was founded on November 13, 2014 and is headquartered in South San Francisco, CA.

Spruce Biosciences Inc

SPRB is trending due to a significant price surge, driven by news of FDA breakthrough designation, leading to community excitement and discussions of potential for further gains. Some traders are comparing it to other high-flying stocks like GLTO and ZNB, while others caution about a potential pullback. The community is actively debating the stock's valuation and future prospects, with some eyeing high price targets.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IONQ is trending as retail traders discuss its high valuation and potential for a pullback, while others point to partnerships and government interest as reasons for continued bullishness. Debate centers around whether the stock is experiencing a short squeeze, and if it can sustain its current market capitalization given its revenue. The community is closely watching key price levels and potential impacts from future earnings reports.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Oppenheimer🏁 $PVLA Outperform/$85: We are launching on Palvella Therapeutics with an Outperform rating and $85 PT. 
 
We like the setup into key clinical readouts over the next six months in indications constituting a $4B TAM. 
 
Our conviction into Qtorin rapamycin&#39;s 1Q26 
single-arm pivotal topline in a rare congenital skin condition is fueled by its strong Phase 2 data. We believe this lead candidate&#39;s Phase 2 reveal next quarter in a second opportunity in same disease category is similarly derisked. 
 
Qtorin rapamycin optimizes topical delivery of a potent mTOR inhibitor, ideally suiting it for skin lesions driven by overactive mTOR which lack good treatment options. 
 
We project &gt;$1B peak sales across microcystic lymphatic and cutaneous venous malformations (MLMs and CVMs, respectively), and believe shares&#39; valuation underappreciates the opportunity.

0wl2000

Chris Veezy

Canaccord Genuity⬆️ $PVLA&#39;s PT to $66 from $52 &amp; reit&#39;d at a Buy. 
$NVS $TARA $MRK $PFE 
Canaccord Genuity said in its research report: 
$PVLA&#39;s 2Q25 earnings report was incremental following enrollment completion of its phase 3 SELVA trial for mLM, which exceeded its target (n=40) by over 25% (n=51). Top-line results are on track for 1Q26. 
 
Ahead of this readout, the most FAQ investor Q has been around Ph3 design + regulatory risk. 
 
We continue to be very comfortable with the former - as a reminder, the trial had 99% power to detect a .5 (vs. 2.42 effect size in Ph2) difference on the primary endpoint before the over enrollment. 
 
On the latter, we remain comfortable with the single-arm trial design and see no outsized clinical risk here (vs. the broader biotech space). 
 
Results of the phase 2 TOIVA trial for the co&#39;s 2nd indication, CVM, remain on track for 4Q25. 
 
The company plans to announce both a third clinical indication for QTORIN rapamycin and a second QTORIN platform candidate in 4Q25.

StockTwits Web

Palvella Therapeutics Inc

Novartis AG

Protara Therapeutics Inc

Merck & Co Inc

Pfizer Inc

Quantumup

H.C. Wainwright reitd $PVLA Buy/$75 after a systemic review of 26 studies assessing the use of rapamycin for the Tx of VMs, fortified the use of QTORIN 3.9% rapamycin in cVMs. 
 
HCW said: A systemic review of 26 studies (n=98) evaluating the use of rapamycin for the treatment of venous malformations was recently published in Lympatic Research and Biology, further supporting the scientific rational and clinical potential of QTORIN 3.9% rapamycin for the treatment of cutaneous venous malformations (cVMs). 
 
There are no FDA approved therapies for the treatment of venous malformations, however off-label use of sirolimus (orally and topically) has demonstrated clinical benefit with the manuscript noting some level of clinical improvement in 72% of the patients. 
 
Based on mixed KOL opinions regarding the validity of the cVM opportunity, we believe that the Phase 2 TOIVA data (expected mid-December) will be an inflection point for the indication. We reiterate our Buy and our price target of $75.

 Outperform/$85: We are launching on Palvella Therapeutics with an Outperform rating and $85 PT. 
 
We like the setup into key clinical readouts over the next six months in indications constituting a $4B TAM. 
 
Our conviction into Qtorin rapamycin's 1Q26 
single-arm pivotal topline in a rare congenital skin condition is fueled by its strong Phase 2 data. We believe this lead candidate's Phase 2 reveal next quarter in a second opportunity in same disease category is similarly derisked. 
 
Qtorin rapamycin optimizes topical delivery of a potent mTOR inhibitor, ideally suiting it for skin lesions driven by overactive mTOR which lack good treatment options. 
 
We project >$1B peak sales across microcystic lymphatic and cutaneous venous malformations (MLMs and CVMs, respectively), and believe shares' valuation underappreciates the opportunity.